目的 探讨儿童急性B 淋巴细胞白血病(B-ALL)巩固化疗期骨髓原血细胞(HGs)对于儿童急性B 淋巴细胞白血病(B-ALL)预后判断的意义.方法 回顾性分析196 例初发B-ALL 患儿,根据危险分型分为高危(n=55)、中危(n=69)和低危(n=72)3 组;根据临床结局分为完全缓解(n=165)和复发组(n=31).采用欧洲BIOMED-1 标准化流式细胞术微小残留病(MRD)检测方案,检测巩固化疗期HGs 数量.Kaplan-Meier 生存曲线统计患儿无事件生存率(EFS).结果 高危组患儿HGs 明显低于中危和低危组,差异均有统计学意义(P<0.05);完全缓解组HGs 明显高于复发组,差异有统计学意义(P<0.05);HGs ≤ 1.0% 组患儿的EFS 明显低于 HGs>1.0% 组,差异有统计学意义(P<0.05).结论 HGs 可反映B-ALL 化疗效果,可用于B-ALL患儿疗效及预后的监测.
Abstract
Objective To study the prognostic value of hematogones (HGs) for childhood B-lineage acute lymphoblastic leukemia (B-ALL) during consolidation chemotherapy. Methods A retrospective analysis was conducted for 196 children with newly-diagnosed B-ALL. They were divided into high-risk group (n=55), intermediate-risk group (n=69), and low-risk group (n=72) by risk stratification, and into complete remission group (n=165) and relapse group (n=31) by clinical outcome. The European BIOMED-1 standard flow cytometry for minimal residual disease (MRD) was used to determine the number of HGs during consolidation chemotherapy. The Kaplan-Meier survival curve was used to assess event-free survival (EFS). Results The high-risk group had a significantly lower number of HGs than the intermediate-risk and low-risk groups (P<0.05). The number of HGs in the complete remission group was significantly higher than in the relapse group (P<0.05). The children with HGs ≤1.0% had a significantly lower EFS than those with HGs >1.0% (P<0.05). Conclusions HGs can be used to assess the treatment outcome and prognosis in children with B-ALL, and proliferation of HGs reflects the good effect of chemotherapy in such children.
关键词
急性B 淋巴细胞白血病 /
流式细胞术 /
原血细胞 /
微小残留病 /
儿童
Key words
B-lineage acute lymphoblastic leukemia /
Flow cytometry /
Hematogone /
Minimal residual disease /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Hurford MT, Altman AJ, DiGiuseppe JA, et al. Unique pattern of nuclear TdT immunofluorescence distinguishes normal precursor B cells (Hematogones) from lymphoblastsof precursor B-lymphoblastic leukemia[J]. Am J Clin Pathol, 2008, 129(5): 700-705.
[2] Sevilla DW, Colovai AI, Emmons FN, et al. Hematogones: a review and update[J]. Leuk Lymphoma, 2010, 51(1): 10-19.
[3] M c K e n n a RW, Wa s h i n g t o n LT, A q u i n o D B, e t a l . Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry[J]. Blood, 2001, 98(8): 2498-2507.
[4] Chantepie SP, Cornet E, Salaün V, et al. Hematogones: an overview[J]. Leuk Res, 2013, 37(11): 1404-1411.
[5] Chantepie SP, Salaün V, Parienti JJ, et al. Hematogones: a new prognostic factor for acute myeloblastic leukemia[J]. Blood, 2011, 117(4): 1315-1318.
[6] Honebrink T, Dayton V, Burke MJ, et al. Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia[J]. Biol Blood Marrow Transplant, 2012, 18(6): 930-936.
[7] Shima T, Miyamoto T, Kikushige Y, et al. Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation[J]. Blood, 2013, 121(5): 840-848.
[8] Lucio P, Gaipa G, van Lochem EG, et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings[J]. Leukemia, 2001, 15(8): 1185-1192.
[9] 陈珊珊. 急性白血病[M]//张之南, 沈悌. 血液病诊断及疗效标准. 第3 版. 北京: 科学出版社, 2007: 132.
[10] Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study[J]. Blood, 2008, 111(12): 5477-5485.
[11] Tsao L, Colovai AI, Jiang JG, et al. Characterizing CD43 expression in haematogones using multicolor flow cytometric analysis[J]. Br J Haematol, 2005, 128(6): 820-823.
[12] LeBien TW. Fates of human B-cell precursors[J]. Blood, 2000, 96(1): 9-23.
[13] LeBien TW, Tedder TF. B lymphocytes: how they develop and function[J]. Blood, 2008, 112(5): 1570-1580.
[14] van der Sluijs-Gelling AJ, van der Velden VH, Roeffen ET, et al. Immunophenotypic modulation in childhood precursor B-ALL can be mimicked in vitro and is related to the induction of cell death[J]. Leukemia, 2005, 19(10): 1845-1847.
[15] Dworzak MN, Gaipa G, Schumich A, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a druginduced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group[J]. Cytometry B Clin Cytom, 2010, 78(3): 147-153.
[16] Chantepie SP, Dugue AE, Chevallier P, et al. Prognostic impact of bone marrow B lymphocyte precursors (hematogones) detection in 95 acute lymphoblastic leukemia cases[C]. ASH Annu Meeting Abstr, 2012, 120: 4791.
[17] Zheng J, Du W, Yao J, et al. Analysis of hematogones in bone marrow from acute myeloid leukaemia cases post therapy[J]. Eur J Clin Invest, 2013, 43(1): 1140-1146.
[18] Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging[J]. Proc Natl Acad Sci USA, 2005, 102(26): 9194-9199.
基金
由四川省科技厅基金项目资助,四川省应用基础研究计划项目(2015JY0044).
PDF(1592 KB)
